Literature DB >> 13671231

Mannomustine in treatment of leukaemias, polycythaemia, and malignant disorders.

A M BARLOW, J T LEEMING, J F WILKINSON.   

Abstract

Entities:  

Keywords:  LEUKEMIA/therapy; MANNITOL/related compounds; NEOPLASMS/therapy; NITROGEN MUSTARDS/therapeutic use; POLYCYTHEMIA/therapy

Mesh:

Substances:

Year:  1959        PMID: 13671231      PMCID: PMC1990033          DOI: 10.1136/bmj.2.5146.208

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  7 in total

1.  The chemotherapy of malignant disease.

Authors:  R B SCOTT
Journal:  Br Med J       Date:  1958-01-04

2.  Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma.

Authors:  D A GALTON; L G ISRAELS; J D NABARRO; M TILL
Journal:  Br Med J       Date:  1955-11-12

3.  Clinical trial of a new nitrogen-mustard compound.

Authors:  C SELLEI; S ECKHARDT; F HARTAI; B DUMBOVICH
Journal:  Lancet       Date:  1956-05-26       Impact factor: 79.321

4.  The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides.

Authors:  A Gilman; F S Philips
Journal:  Science       Date:  1946-04-05       Impact factor: 47.728

5.  Clinical observations with 1, 6-bis(beta-chloroethylamino)-1, 6-deoxy-D-mannitol dihydrochloride (BCM) in malignant diseases.

Authors:  C SELLEI; S ECKHARDT
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

6.  Treatment of Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia vera, and other reticuloses with triethylenethiophosphoramide.

Authors:  M C ISRAELS; B J LEONARD; J F WILKINSON
Journal:  Lancet       Date:  1956-11-17       Impact factor: 79.321

7.  Discussion on the chemotherapy of the reticuloses.

Authors:  J F WILKINSON; A HADDOW; J D NABARRO
Journal:  Proc R Soc Med       Date:  1953-09
  7 in total
  1 in total

1.  The Clinical Application of Bone Marrow Grafting.

Authors:  D E Pegg; J G Humble; K A Newton
Journal:  Br J Cancer       Date:  1962-09       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.